PACS

ANALYST NOTE: PACS (PACS Group, Inc.) Date: 2026-06-20 Subject: Structural Setup Analysis & Business Fundamentals

1. Structural Readiness

Current State: Forming Price Action: The stock is currently trading at $36.59, which is below the breakout threshold but holding above the critical support line.

• Conservative Entry: Not yet available (requires confirmed breakout).
• Aggressive Entry: $38.98 (Pre-breakout / forming entry).
• Breakout Level: $43.08 (Resistance level that must be cleared to confirm the setup).
• Extension: None (Price is currently in the base formation, not extended).
• Volatility Context: Current ATR is 5.0% (High). This places the stock in the historical "sweet spot" for structural quality, indicating sufficient volatility to support a move without being in the "extreme" danger zone (>8%).

2. Thesis Layer

Thesis Classification: TACTICAL / Setup-Led Macro Context: As of this date, there is no named secular thesis attached to this specific setup. The investment case is not driven by a specific macro narrative (e.g., "Silver Bullet" or "Demographic Super-Cycle" thesis) but is strictly driven by the quality of the technical structure combined with the fundamental business performance. Judgment Criteria: The name must be judged on the integrity of the forming coil structure and the strength of the underlying business fundamentals (EBITDA growth, occupancy, and margin expansion) rather than external thematic tailwinds.

3. Business Fundamentals

Company Overview: PACS Group, Inc. is a leading post-acute healthcare company focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities. Business Model: The company operates a mix of Skilled Nursing Facilities (SNF), Assisted Living, and Independent Living facilities. Revenue is generated primarily through third-party payors, specifically Medicare and Medicaid. Operational Scale (as of March 31, 2026):

• Portfolio: 323 facilities across 17 states.
• Capacity: Approximately 35,500 total beds (32,700 skilled nursing, 2,700 assisted living).
• Patient Volume: Serving approximately 31,900 patients daily.
• Growth: Expanded operations by adding three assisted living and independent living facilities in Q1 2026 (two via acquisition with real estate, one via long-term lease).

Financial Performance & Guidance (as of May 12, 2026):

• Revenue Guidance: Reaffirmed range of $5.65 billion to $5.75 billion for full-year 2026.
• EBITDA Guidance: Significantly increased adjusted EBITDA guidance to $605 million to $625 million, a $50 million increase at all levels relative to prior guidance.
• Growth Rate: The midpoint of the new EBITDA range represents approximately 22% growth over 2025.
• Revenue Mix: Skilled nursing services revenue for the three months ended March 31, 2026, was $1.378 billion, up 9.9% year-over-year.
• Historical Context: For the year ended December 31, 2025, total revenue was $5.3 billion, representing a 30.4% CAGR over the last three years.

Operational Quality:

• Occupancy: Mature facilities operated at 94.8% occupancy with a skilled mix of 33%. The full portfolio occupancy rate was 90.8% (up 160 bps from prior period).
• Quality Ratings: 222 facilities are rated 4 or 5 stars under CMS Quality Measure ratings (up from 207 at end of 2025). The average QM Star rating for mature facilities is 4.4, compared to 3.6 for new facilities.
• Acquisition Pipeline: Management expects to remain active on the acquisition front, with discussions ongoing on several opportunities to potentially close during 2026.

4. Archetype and Conviction

Archetype: Margin Inflector Rationale: The company fits the "Margin Inflector" archetype due to the significant expansion in adjusted EBITDA guidance ($50M increase) while maintaining revenue guidance. The data shows a clear decoupling of top-line growth from bottom-line efficiency, driven by high occupancy in mature facilities (94.8%) and a high-quality star rating profile (4.4 stars for mature assets). The shift from a 3.6-star average for new facilities to a 4.4-star average for mature facilities suggests a successful ramp-up and operational inflection point where assets are converting to higher-margin, stable cash flows.

Conviction Stack:

• Thesis Strength: Moderate (Tactical/Setup-led, no external macro thesis).
• Evidence Quality: High. Management has provided specific, quantitative guidance updates (EBITDA +22% growth) and operational metrics (occupancy, star ratings) that confirm the thesis.
• Setup Readiness: Partial. The coil is forming but has not fired. The 69% historical breakout rate for this state is a positive bias but does not guarantee the move.
• Rerating Potential: Significant. The combination of 22% EBITDA growth and a 30.4% revenue CAGR suggests the market may be underpricing the operational leverage of the mature facility portfolio.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• A daily close above $43.08 (Breakout Level), confirming the coil structure.
• Further confirmation of the acquisition pipeline closing in Q2 2026.
• Continued maintenance of >94% occupancy in mature facilities.

What Would Invalidate the Case:

• A significant miss on the reaffirmed revenue guidance or a reduction in EBITDA expectations.

Gaps in Evidence:

• Valuation Multiples: While financial growth is strong, specific P/E or EV/EBITDA multiples relative to peers are not provided in the current evidence block.
• Debt Structure: No specific details on leverage ratios or debt maturity schedules are available in the provided excerpts, though the acquisition strategy implies capital deployment.
• Regulatory Risk: While CMS ratings are high, the specific exposure to potential Medicare/Medicaid reimbursement rate changes in 2026 is not detailed beyond the general industry context.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key risks: Technical invalidation if price closes below $35.05; Regulatory reimbursement pressure from Medicare/Medicaid; Execution risk on the stated acquisition pipeline. Expected path: Management expects to close several acquisition opportunities in 2026; operational leverage from mature facilities should continue to drive EBITDA expansion; price likely to test $43.08 resistance if volume supports the breakout. Expected horizon: 3 to 6 months for the structural setup to resolve (breakout or invalidation). Failure mode to watch: A sustained daily close below $35.05, which would confirm the coil structure has failed and the setup is invalidated.